Neuroendocrine Tumors: From Diagnosis to Therapy
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 August 2024 | Viewed by 1387
Special Issue Editors
Interests: imaging; oncology; CT; MRI; artificial intelligence; radiomics; response to therapy
Special Issues, Collections and Topics in MDPI journals
Interests: neuroendocrine tumors; digestive oncology; pancreatic diseases; gut hormones
Special Issues, Collections and Topics in MDPI journals
Interests: nuclear medicine; PET/CT; response to therapy; PRRT
Interests: imaging; oncology; CT; MRI; artificial intelligence; radiomics; response to therapy
Special Issue Information
Dear Colleagues,
Neuroendocrine neoplasms (NENs) are considered rare tumors with a wide spectrum of behaviors, manly indolent, but are highly dependent on the presence of high-risk clinical features (such as metastatic disease, grading, ki67, the expression of somatostatin receptors, and primary sites). Diagnoses, using a dual morphological and functional approach in NENs, are based on histology and imaging.
However, these conventional evaluations can have some intrinsic drawbacks, from the limited tissue sampling, in the case of tumor biopsy, to the bias linked to the subjective assessment of medical images. Furthermore, based on the assessment of response to therapy, the morphological RECIST 1.1 criteria could be reductive and not appropriate, especially in the case of target therapy.
In this context, quantitative imaging has acquired relevance as a supporting tool for clinicians in order to overcome the limits associated with the conventional approach, especially in prediction prognosis and in response to therapy. Thus, to outline a structured therapeutic path, one of the future landscapes of NEN management may be the integration of quantitative imaging with conventional evaluations.
This Special Issue will highlight the main strengths and limitations in the management of NENs, from the diagnosis to the response to therapy, and will investigate the emerging role of quantitative biomarkers.
Dr. Damiano Caruso
Prof. Dr. Francesco Panzuto
Dr. Daniela Prosperi
Dr. Michela Polici
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neuroendocrine neoplasms
- CT
- MR
- PET/CT
- target therapy
- quantitative biomarkers